Paul is a Health Economics Manager at Health Technology Analysts (HTanalysts) and a senior member of the Health Services Assessment Collaboration (HSAC). Paul is a member of the Australian Health Economics Society (AHES), the Australian Association for Regulatory and Clinical Scientists (ARCS) and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
Since commencing work as a health economist in 2002, Paul has provided strategic advice to the pharmaceutical industry by drawing on his expertise in economic modelling. Paul has gained experience in this time by working in a number of environments including the PBAC, NICE and a number of European and North American countries. In addition to pharmacoeconomic modelling, Paul has also been responsible for the development of a number of models in the area of screening and diagnostic testing. Additionally, Paul has acted as an evaluator for the Medical Services Advisory Committee (MSAC), Australia.
Paul holds a first class honours degree in Economics and Masters of Commerce specialising in Economics. Paul has completed courses in Advanced Modelling Methods for Economic Evaluation conducted by the University of York and has also been trained in the advanced application of TreeAge Pro decision analytic software.
Paul’s research interests include health economic modelling of diagnostic and screening tests, and pharmaceuticals. Paul also holds an interest in determination of preference-based utility weights for use in economic evaluations.
Recent publications/Reports
Standfield L, Mernagh P, Norris S. Cost-effectiveness of the Thin Prep® System for population screening for cervical cancer in Australian Women. Oral presentation at the 6th Annual Meeting of Health Technology Assessment International (HTAI). Singapore 2009
Mernagh P, Suebwongpat A, Silverberg J, Weston A (2009) Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer: the Canadian perspective Value in Health (accepted)
Pereira J, Weston A, Mernagh P, Silva R, Barbosa P, Rodrigues E, Carrilho F, Rodrigues F, Cruz-Ferreira T, Limbert E. Economic evaluation of using recombinant human TSH prior to radioiodine ablation for thyroid cancer in Portugal. Conference presentation European Thyroid Association, Greece, 2008
Pereira J; Mernagh P, Silva AR; Limbert E; Weston A (2007) Analise custo-utilidade do uso da TSH human recombinante antes de ablacao com radioiodo na neoplasia de tiroide. Conference presentation 10th Portugese Conference on Health Economics, November
Mernagh P, Campbell S, Dietlein M, Luster M, Mazzaferri E, Weston AR (2006) Cost-effectiveness of using recombinant thyroid stimulating hormone (rhTSH) prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective Eur J Endocrin 155(3):405-14